Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

- (10) ------------------------- Net loss $ 3,044 $ 2,409 Condensed Consolidated Balance Sheets (in thousands) March 31, December 31, 2010 2009 (unaudited) Assets: Cash, cash equivalents and short term investments $ 47,586 $ 64,568 Restricted cash 3,502 - Amounts receivable 2,823 3,109 Prepaid and other current assets 1,938 722 Property, equipment and other assets 589 581 ------------------------- Total assets 56,438 $ 68,980 ------------------------- ------------------------- Liabilities and stockholders' equity: Accounts payable and accrued expenses 6,824 $ 14,453 Deferred collaboration revenue 24,611 26,528 Other current liabilities 1,307 1,328 Long term liabilities 3,427 3,712 Stockholders' equity (deficiency) 20,269 22,959 ------------------------- Total liabilities and stockholders' equity (deficiency) 56,438 $ 68,980 -------------------------
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Corp ., a non-profit development company that helps small businesses, ... technology businesses. , ,MDC said it has closed on loans ... off of Lucigen Corp. , and to BioSystem ... Contest. , ,C5-6 Technologies, which will develop enzymes used to ...
... series of articles on developing start-up companies in the technology or ... entity. , , Madison, Wis. - Now ... to the type of entity to use, you should have concerned ... people think of first. Income taxes depend upon the type of ...
... - Jim Rice, who has served as president and CEO ... the past year, will leave ITAWi after an agreed-upon transition ... organization announced. , ,ITAWi's Board of Director has begun ... will assume Rice's duties until a replacement is found. Rice ...
Cached Biology Technology:Early Stage: Step 6 - Taxes, taxes, taxes! 2Early Stage: Step 6 - Taxes, taxes, taxes! 3Early Stage: Step 6 - Taxes, taxes, taxes! 4Rice to leave Wisconsin technology association 2
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Virology of the GSF National Research Center for ... Research Centres) the group is continuing to search for ... of a prion infection. In collaboration with colleagues from ... Heidelberg, the group used micro-array technologies micro-arrays ...
... plant cell biologist at UC Riverside has received a ... investigate how plant stem-cells maintain their identity and how ... According to G. Venugopala Reddy, the principal investigator of ... on plants, has potential to lead to better insights ...
... infant formula-- may reduce a babys susceptibility to rotavirus ... a University of Illinois study published in Septembers Journal ... diarrhea in infants, affecting virtually all children before age ... dehydration, doctors visits, and parents missing work to care ...
Cached Biology News:Prions and retroviruses -- an unholy alliance? 2UCR plant cell biologist to study how plant stem cells maintain and change their identity 2Soy isoflavone may inhibit common gastrointestinal illness in infants 2
Request Info...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Blimp-1 (H-150)...
Biology Products: